[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"primary-immune-deficiency-disorder\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:primary-immune-deficiency-disorder":24},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,38,66,99,125,145],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":26,"lastUpdatePostDateStruct":27,"startDateStruct":30,"completionDateStruct":32,"leadSponsor":34,"locationsCount":37},"100318198","pathophysiology-of-inborn-immunodeficiencies-100318198",false,"NCT03422614","Pathophysiology of Inborn Immunodeficiencies","Pathophysiologie Angeborener Immundefekte","Inclusion Criteria:\n\n* Clinical diagnosis of an inborn error of immunity (primary immunodeficiency, PID)\n* Clinically healthy (non-age matched) volunteer\n\nExclusion Criteria:\n\n* exclusion of an inborn error of immunity\n* secondary immunodeficiency\n* refusal to enter the study",true,"ALL",{"count":19,"type":20},300,"ESTIMATED","OBSERVATIONAL","The pathophysiology of primary immunodeficiencies (PID), which encompass a broad range of different diseases with susceptibility to infection and\u002For a deregulated inflammatory response, is poorly understood. Available treatments are often not specific for a distinct target and might be associated with side effects. To elucidate pathophysiology of different PIDs, stool, urine, blood, tissue biopsies and\u002For bone marrow will be collected and analysed for anti-microbial activity and inflammatory response. In a second step, targeted treatment for different PIDs might be developed preclinically and ex vivo according to underlying pathophysiology.",[24],"Primary Immune Deficiency Disorder","RECRUITING","2026-05-05",{"date":28,"type":29},"2026-05-06","ACTUAL",{"date":31,"type":29},"2015-03-01",{"date":33,"type":20},"2033-03-30",{"name":35,"class":36},"University of Zurich","OTHER",1,{"id":39,"slug":40,"hasResults":11,"nctId":41,"briefTitle":42,"officialTitle":43,"acronym":4,"eligibilityCriteria":44,"healthyVolunteers":11,"sex":17,"minAge":45,"maxAge":46,"enrollmentInfo":47,"targetDuration":4,"studyType":49,"phases":50,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":65},"100377674","phase-1-treatment-of-refractory-bk-infections-with-related-donor-bk-specific-cytotoxic-t-cells-ctls-100377674","NCT04197596","Treatment of Refractory BK Infections With Related Donor BK Specific Cytotoxic T-cells (CTLs)","A Pilot Study in the Treatment of Refractory BK Infections With Related Donor BK Specific Cytotoxic T-cells (CTLs) in Children, Adolescents and Young Adult Recipients","Inclusion Criteria:\n\n.1.1 Patients with refractory BK infection post allogeneic HSCT, post solid organ transplantation or with primary immunodeficiencies with either\n\n* Increasing urine and\u002For plasma BK RT-PCR DNA (by 1 log) after 7 days or persistent quantitative qRT-PCR DNA copies after 14 days despite two weeks of appropriate anti-viral therapy AND\u002FOR\n* Medical intolerance to anti-viral therapies including:\n\n  * 2 renal toxicity with cidofovir or other \\> grade 2 toxicities secondary to cidofovir And\u002For\n* known resistance to cidofovir 1.2. Consent: Written informed consent given (by patient or legal representative) prior to any study-related procedures.\n\n1.3 Performance Status \\> 30% (Lansky \\\u003C 16 yrs and Karnofsky \\> 16 yrs) 1.4 Age: 0.1 to 79.99 years 1.5 Females of childbearing potential with a negative urine pregnancy test\n\nExclusion:\n\n1. Patient with acute GVHD \\> grade 2 or extensive chronic GVHD at the time of BK CTL infusion\n2. Patient receiving steroids (\\>0.5 mg\u002Fkg prednisone equivalent) at the time of BK CTL infusion\n3. Patient treated with donor lymphocyte infusion (DLI) within 4 weeks prior to BK CTL infusion\n4. Thymoglobulin (ATG) or Alemtuzumab within 30 days\n5. Patient with poor performance status determined by Karnofsky (patients \\>16 years) or Lansky (patients ≤16 years) score ≤30%\n6. Concomitant enrollment in another experimental clinical trial investigating the treatment of refractory BK infection.\n7. Any medical condition which could compromise participation in the study according to the investigator's assessment\n8. Known HIV infection\n9. Female patient of childbearing age who is pregnant or breast-feeding or not willing to use an effective method of birth control during study treatment.\n10. Known hypersensitivity to iron dextran\n11. Patients unwilling or unable to comply with the protocol or unable to give informed consent.\n12. Known human anti-mouse antibodies","1 Month","79 Years",{"count":48,"type":20},40,"INTERVENTIONAL",[51,52],"PHASE1","PHASE2","BK cytotoxic T cells (CTLs) manufactured with the Miltenyi CliniMACS Prodigy Cytokine Capture System will be safe and effective in decreasing specific viral load in children, adolescents and young adults (CAYA) with refractory BK infection post Allogeneic Hematopoietic Stem Cell Transplantation (AlloHSCT) or with primary immunodeficiencies (PID).",[55,24],"Viral Infection","2026-04-10",{"date":58,"type":29},"2026-04-15",{"date":60,"type":29},"2020-07-01",{"date":62,"type":20},"2027-06-30",{"name":64,"class":36},"New York Medical College",7,{"id":67,"slug":68,"hasResults":11,"nctId":69,"briefTitle":70,"officialTitle":70,"acronym":4,"eligibilityCriteria":71,"healthyVolunteers":11,"sex":17,"minAge":72,"maxAge":73,"enrollmentInfo":74,"targetDuration":4,"studyType":49,"phases":76,"briefSummary":77,"conditions":78,"keywords":88,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":37},"100380322","phase-2-regenerative-medicine-to-restore-hematopoiesis-and-immune-function-in-immunodeficiencies-and-inherited-bone-marrow-failures-100380322","NCT04232085","Regenerative Medicine to Restore Hematopoiesis and Immune Function in Immunodeficiencies and Inherited Bone Marrow Failures","Inclusion Criteria\n\nCohort A:\n\nPrimary Immune Deficiencies with indication for HCT:\n\n* Chronic granulomatous disease (CGD)\n* Wiskott-Aldrich syndrome (WAS)\n* Hyper-IgM syndrome\n* Common variable immunodeficiency (CVID)\n* Leukocyte adhesion deficiency-1 (LAD-1)\n* Severe Combined Immunodeficiency (SCID)\n* CTLA-4 deficiency\n* CARD9 deficiency\n* DOCK8 deficiency\n\nImmune Dysregulatory Syndromes:\n\n* Immunodysregulation polyendocrinopathy enteropathy X-linked (IPEX) syndrome\n* Hemophagocytic lymphohistiocytosis (HLH) or related disorder with indication for transplant\n* CAEBV: Patients with chronic EBV infection (CAEBV) with indication for BMT:\n\nInherited Bone marrow failure disorders\n\n* Congenital amegakaryocytic thrombocytopenia (CAMT)\n* Diamond Blackfan anemia (DBA)\n* Shwachman Diamond Syndrome (SDS)\n* Thrombocytopenia Absent Radii (TAR)\n* Glanzmans thrombasthenia (GT)\n* Kostmann syndrome\n* Other indications and\u002For other PID, IDS, and IBMFS diagnoses as deemed appropriate by the PI.\n\nCohort B: Short telomere syndrome\n\nCohort C: Confirmed diagnosis of Fanconi anemia or non-Fanconi DNA-dsb repair disorders\n\n* Fanconi anemia\n* Non-Fanconi DNA-dsb repair disorders\n* Cerunnos-XRCC4-like factor deficiency (XLF or NHEJ1)\n* DNA ligase IV deficiency (LIG4)\n* Nijmegen breakage syndrome (NBS)\n* Increased DNA breakage after exposure of patient cells to DNA cross-linking agents such as diepoxybutane or mitomycin C and germline mutation(s) in an identified Fanconi pathway gene.\n\nAvailable donor as follows:\n\n* Fully HLA matched sibling or other first-degree family member.\n* Fully HLA matched unrelated 10\u002F10 donor using high-resolution DNA-based typing at the following genetic loci: HLA-A, -B, -C, DRB1, and DQB1.\n* Mismatched unrelated donor at 8 or 9\u002F10 alleles, using high-resolution typing as above.\n* HLA-haploidentical family members of any degree who match at least one allele of each of the following genetic loci: HLA-A, -B, -C, DRB1, and DQB1. A minimum match of 5\u002F10 is therefore required, and will be considered sufficient evidence that the donor and recipient share one HLA haplotype.\n* The patient and\u002For legal guardian must sign informed consent for BMT.\n* Patients with adequate organ function as measured by\n* Cardiac: Left ventricular ejection fraction (LVEF) at rest must be ≥ 35%. For patients aged \\\u003C13 years, shortening fraction (SF) \\> 25% by echocardiogram or LVEF by MUGA may be used.\n* Hepatic: Bilirubin ≤ 3.0 mg\u002FdL; and ALT, AST, and Alkaline Phosphatase \\\u003C 5 x ULN.\n* Renal: Serum creatinine within normal range for age, or if serum creatinine outside normal range for age, then renal function (creatinine clearance or GFR) \\> 40 mL\u002Fmin\u002F1.73m2.\n* Pulmonary: PFT with FEV1 and FVC \\>\u002F= 50% of normal and DLCO corrected for Hgb \\>\u002F= 40% of normal. Patients unable to undergo PFTs should have stable resp status with SaO2 \\>90% on a max of 2L\u002Fmin supplemental O2.\n* Karnofsky or Lansky performance status ≥70%\n* Females and males of childbearing potential must agree to practice 2 effective methods of contraception at the same time, or agree to abstinence.\n\nExclusion criteria\n\n* Patients will not be excluded on the basis of sex, racial or ethnic background.\n* Positive leukocytotoxic crossmatch.\n* Prior allogeneic stem cell transplant.\n* Uncontrolled bacterial, viral, or fungal infection at the time of enrollment. Uncontrolled is defined as currently taking medication and with progression or no clinical improvement on adequate medical treatment. The investigators recognize that patients with CAEBV may have ongoing EBV viremia at the time of initiating pre-transplant therapy, but other patients should have no uncontrolled bacterial, viral, or fungal infections.\n* Diagnosis of idiopathic aplastic anemia\n* Seropositivity for the human immunodeficiency virus (HIV)\n* Active Hepatitis B or C determined by serology and\u002For NAT\n* Female patients who are diagnosed as pregnant by beta bHCG testing (per institutional practice) or who are breast-feeding.\n* Active malignancy or within the timeframe for significant concern for relapse of prior malignancy\n* For Cohort B and C: liver biopsy (if performed, not required) with moderate-severe fibrosis\u002Fcirrhosis\n\nDonor Eligibility\n\n* Donor must be medically, socially, and psychologically fit to donate\n* Bone marrow is the preferred graft source, however, PBSCs may be requested. In particular, PBSCs may be preferred for patients with active viral reactivations and\u002For for patients who would benefit from a higher count in the graft. Cord blood is not permitted.\n* First-degree relatives should be tested for degree of HLA match, CMV serology, ABO type, and complete blood count (CBC). An unrelated donor search should be initiated at the time the patient is referred for BMT.\n* Age ≥5 years\n* Donors must meet the selection criteria as defined by the Foundation for the Accreditation of Hematopoietic Cell Therapy (FACT).\n* Lack of recipient anti-donor HLA antibody in recipient\n* Note: In some instances, low level, non-cytotoxic HLA specific antibodies may be permissible if found to be at a level well below that detectable by flow cytometry. This will be decided on a case-by-case basis by the PI and one of the immunogenetics directors.\n* In inherited disorders, family members must be tested for carrier and disease status of the underlying disorders. In the event that family members are unaffected carriers, eligibility as donors will be decided upon by the PI on a case-by-case basis\n* In the event that two or more eligible donors are identified, the donor will be selected per institutional standards. Suggested criteria include the following:\n* Related is preferred over unrelated.\n* The potential donor that is youngest in age is preferred.\n* For CMV seronegative patients, a CMV seronegative donor is preferred. For CMV seropositive patients, a CMV seropositive donor is preferred.\n* Red blood cell compatibility, in order of preference:\n* RBC cross match compatible Minor ABO incompatibility, Major ABO incompatibility\n* If the patient is male, male donors are preferred.","4 Months","50 Years",{"count":75,"type":20},27,[52],"Phase II prospective trial to assess the rates of donor engraftment using reduced intensity conditioning (RIC) hematopoietic stem cell transplant (HSCT) and post-transplant cyclophosphamide (PTCy) for patients with primary immune deficiencies (PID), immune dysregulatory syndromes (IDS), inherited bone marrow failure syndromes (IBMFS), short telomere syndromes, Fanconi anemia, and non-Fanconi DNA double-strand break (DNA-dsb) repair disorder.",[24,79,80,81,82,83,84,85,86,87],"Immune Deficiency Disease","Bone Marrow Failure","Short Telomere Length","Fanconi Anemia","Non Fanconi DNA-DSB Repair Disorder","Hoyeraal-Hreidarsson Syndrome","Dyskeratosis Congenita","Telomere Biology Disorder","Short Telomere Syndrome",[89],"Bone Marrow Transplantation","2025-11-21",{"date":92,"type":29},"2025-11-28",{"date":94,"type":29},"2020-02-12",{"date":96,"type":20},"2028-12-31",{"name":98,"class":36},"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins",{"id":100,"slug":101,"hasResults":11,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":4,"eligibilityCriteria":105,"healthyVolunteers":11,"sex":17,"minAge":45,"maxAge":46,"enrollmentInfo":106,"targetDuration":4,"studyType":49,"phases":108,"briefSummary":109,"conditions":110,"keywords":112,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":124},"100306238","phase-2-adenovirus-specific-cytotoxic-t-lymphocytes-for-refractory-adenovirus-infection-100306238","NCT03266627","Adenovirus-specific Cytotoxic T-lymphocytes for Refractory Adenovirus Infection","A Pilot Study in the Treatment of Refractory Adenovirus (ADV) Infection With Related Donor ADV Cytotoxic T-Lymphocytes (ADV-CTLs)in Children, Adolescents and Young Adult Recipients","1. Patients with Adenovirus infections post allogeneic HSCT, with primary immunodeficiencies or post solid organ transplant with:\n\n   * Increasing or persistent quantitative ADV RT-PCR DNA copies despite two weeks of appropriate anti-viral therapy and\u002For\n   * clinical symptoms attributed to adenovirus, including pneumonitis, hemorrhagic cystitis, colitis, hepatitis AND\u002FOR\n   * Medical intolerance to anti-viral therapies including:\n\n     * grade 2 renal insufficiency secondary to cidofovir Consent: Written informed consent given (by patient or legal representative) prior to any study-related procedures.\n\n   Performance Status \\> 30% (Lansky \\\u003C 16 yrs and Karnofsky \\> 16 yrs) Age: 0.1 to 79 years\n\n   Females of childbearing potential with a negative urine pregnancy test\n2. Donor Eligibility Related donor available with a T-cell response to the viral MACS® GMP PepTivator antigen(s) of adenovirus.\n\n   a. Third Party Related Allogeneic Donor: If original donor is not available or does not have a T-cell response: third party allogeneic donor (family donor \\> 1 HLA A, B, DR match to recipient) with a T-cell response at least to the viral MACS® GMP PepTivator antigen(s) of adenovirus.\n\n   AND Allogeneic donor disease screening is complete similar to hematopoietic stem cell donors (Appendix 1).\n\n   AND Obtained informed consents by donor or donor legally authorized representative prior to donor collection.\n3. Patient exclusion criteria:\n\nA patient meeting any of the following criteria is not eligible for the present study:\n\n. Patient with acute GVHD \\> grade 2 or extensive chronic GVHD at the time of CTL infusion Patient receiving steroids (\\>0.5 mg\u002Fkg prednisone equivalent) at the time of CTL infusion Patient treated with donor lymphocyte infusion (DLI) within 4 weeks prior to CTL infusion Patient with poor performance status determined by Karnofsky (patients \\>16 years) or Lansky (patients ≤16 years) score ≤30% Concomitant enrollment in another experimental clinical trial investigating the treatment of refractory adenovirus infection(s) Any medical condition which could compromise participation in the study according to the investigator's assessment Known HIV infection Female patient of childbearing age who is pregnant or breast-feeding or not willing to use an effective method of birth control during study treatment.\n\nKnown hypersensitivity to iron dextran Patients unwilling or unable to comply with the protocol or unable to give informed consent.\n\nKnown human anti-mouse antibodies\n\n\\-",{"count":107,"type":20},20,[52],"Related donor Adenovirus (ADV) specific cytotoxic T cells (CTLs) manufactured with the Miltenyi CliniMACS Prodigy Cytokine Capture System will be administered intravenously in in children, adolescents and young adults with refractory ADV infection post Allogeneic Hematopoietic Stem Cell Transplantation (AlloHSCT), with primary immunodeficiencies (PID) or post solid organ transplant.\n\nFunding Source: FDA OOPD",[111,24],"Adenovirus",[113,114,115],"adenovirus","primary immune deficiency disorder","cytotoxic t-lymphocytes","2025-08-07",{"date":118,"type":29},"2025-08-08",{"date":120,"type":29},"2018-11-01",{"date":122,"type":20},"2027-12-31",{"name":64,"class":36},10,{"id":126,"slug":127,"hasResults":11,"nctId":128,"briefTitle":129,"officialTitle":130,"acronym":4,"eligibilityCriteria":131,"healthyVolunteers":11,"sex":17,"minAge":45,"maxAge":46,"enrollmentInfo":132,"targetDuration":4,"studyType":49,"phases":133,"briefSummary":134,"conditions":135,"keywords":137,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":140,"startDateStruct":141,"completionDateStruct":142,"leadSponsor":143,"locationsCount":144},"100306239","phase-2-virus-specific-cytotoxic-t-lymphocytes-ctls-for-refractory-cytomegalovirus-cmv-100306239","NCT03266640","Virus Specific Cytotoxic T-Lymphocytes (CTLs) for Refractory Cytomegalovirus (CMV)","A Pilot Study in the Treatment of Refractory Cytomegalovirus (CMV) Infections With Related Donor CMV Specific Cytotoxic T-cells (CTLs) in Children, Adolescents and Young Adult Recipients","1\\. Patients with refractory CMV infection post allogeneic HSCT, with primary immunodeficiencies or post solid organ transplant with either\n\n* Increasing or persistent quantitative qRT-PCR DNA copies despite two weeks of appropriate anti-viral therapy AND\u002FOR\n* Medical intolerance to anti-viral therapies including:\n* ANC \\\u003C 500\u002Fmm2 secondary to ganciclovir\n\n  * 2 renal toxicity with foscarnet And\u002For\n* known resistance to ganciclovir and\u002For foscarnet\n\nConsent: Written informed consent given (by patient or legal representative) prior to any study-related procedures.\n\nPerformance Status \\> 30% (Lansky \\\u003C 16 yrs and Karnofsky \\> 16 yrs) Age: 0.1 to 79.99 years Females of childbearing potential with a negative urine pregnancy test\n\nDonor Eligibility Related donor available with a T-cell response to the CMV MACS® GMP PepTivator antigen(s).\n\na. Third Party Allogeneic Donor: If original donor is not available or does not have a T-cell response: third party related allogeneic donor (family donor \\> 1 HLA A, B, DR match to recipient) with IgG positive to CMV and\u002For a T-cell response to the CMV MACS® GMP PepTivator .\n\nAND Allogeneic donor disease screening is complete similar to hematopoietic stem cell donors (Appendix 1).\n\nAND Obtained informed consents by donor or donor legally authorized representative prior to donor collection.\n\n3 Patient exclusion criteria:\n\nA patient meeting any of the following criteria is not eligible for the present study:\n\nPatient with acute GVHD \\> grade 2 or extensive chronic GVHD at the time of CMV CTL infusion Patient receiving steroids (\\>0.5 mg\u002Fkg prednisone equivalent) at the time of CMV CTL infusion Patient treated with donor lymphocyte infusion (DLI) within 4 weeks prior to CMV CTL infusion Thymoglobulin (ATG), Alemtuzumab or T cell immunosuppressive monoclonal antibodies within 30 days Patient with poor performance status determined by Karnofsky (patients \\>16 years) or Lansky (patients ≤16 years) score ≤30% CMV retinitis Concomitant enrollment in another experimental clinical trial investigating the treatment of refractory CMV infection.\n\nAny medical condition which could compromise participation in the study according to the investigator's assessment Known HIV infection Female patient of childbearing age who is pregnant or breast-feeding or not willing to use an effective method of birth control during study treatment.\n\nKnown hypersensitivity to iron dextran Patients unwilling or unable to comply with the protocol or unable to give informed consent.\n\nKnown human anti-mouse antibodies CMV retinitis, meningitis, encephalitis, and\u002For cerebritis",{"count":107,"type":20},[52],"CMV cytotoxic T cells (CTLs) manufactured with the Miltenyi CliniMACS Prodigy Cytokine Capture System will be administered in children, adolescents and young adults (CAYA) with refractory cytomegalovirus (CMV) infection post Allogeneic Hematopoietic Stem Cell Transplantation (AlloHSCT), with primary immunodeficiencies (PID) or post solid organ transplant.\n\nFunding Source: FDA OOPD",[136,24],"Cytomegalovirus Infections",[138,139,115],"Cytomegalovirus","CMV",{"date":118,"type":29},{"date":120,"type":29},{"date":122,"type":20},{"name":64,"class":36},9,{"id":146,"slug":147,"hasResults":11,"nctId":148,"briefTitle":149,"officialTitle":150,"acronym":4,"eligibilityCriteria":151,"healthyVolunteers":11,"sex":17,"minAge":45,"maxAge":46,"enrollmentInfo":152,"targetDuration":4,"studyType":49,"phases":153,"briefSummary":154,"conditions":155,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":157,"startDateStruct":158,"completionDateStruct":160,"leadSponsor":161,"locationsCount":162},"100306240","phase-2-ebv-specific-cytotoxic-t-lymphocytes-ctls-for-refractory-ebv-infection-100306240","NCT03266653","EBV-specific Cytotoxic T-lymphocytes (CTLs) for Refractory EBV Infection","A Pilot Study in the Treatment of Refractory Epstein-Barr Virus (EBV) Infection With Related Donor EBV Cytotoxic T-Lymphocytes in Children, Adolescents and Young Adult Recipients","1\\. Patients with Epstein-Barr virus infections post allogeneic HSCT, primary immunodeficiencies or post solid organ transplant with:\n\n* Increasing or persistent quantitative EBV RT-PCR DNA copies despite two weeks of appropriate anti-viral therapy and\u002For\n* progressive clinical symptoms attributable to EBV, including biopsy proven colitis, lymphadenopathy, hepatomegaly, splenomegaly AND\u002FOR\n* Medical intolerance to anti-viral therapies including:\n* intolerance to rituximab Consent: Written informed consent given (by patient or legal representative) prior to any study-related procedures.\n\nPerformance Status \\> 30% (Lansky \\\u003C 16 yrs and Karnofsky \\> 16 yrs) Age: 0.1 to 79.99 years Females of childbearing potential with a negative urine pregnancy test\n\n2 Donor Eligibility 5.2.1 Related donor available with a T-cell response to the EBV MACS® GMP PepTivator antigen(s) causing the therapy-refractory EBV infection.\n\na. Third Party Related Allogeneic Donor: If original donor is not available or does not have a T-cell response: third party related allogeneic donor (family donor \\> 1 HLA A, B, DR match to recipient) with IgG positive to EBV and\u002For a T-cell response at least to the viral MACS® GMP PepTivator EBV Select (containing among other antigens, NA-1, LMP2A and BZLF-1).\n\nAND Allogeneic donor disease screening is complete similar to hematopoietic stem cell donors (Appendix 1).\n\nAND Obtained informed consents by donor or donor legally authorized representative prior to donor collection.\n\n3 Patient exclusion criteria:\n\nA patient meeting any of the following criteria is not eligible for the present study:\n\nPatient with acute GVHD \\> grade 2 or extensive chronic GVHD at the time of CTL infusion Patient receiving steroids (\\>0.5 mg\u002Fkg prednisone equivalent) at the time of CTL infusion Patient treated with donor lymphocyte infusion (DLI) within 4 weeks prior to CTL infusion Patient with poor performance status determined by Karnofsky (patients \\>16 years) or Lansky (patients ≤16 years) score ≤30% Concomitant enrollment in another experimental clinical trial investigating the treatment of refractory EBV infection Any medical condition which could compromise participation in the study according to the investigator's assessment Known HIV infection Female patient of childbearing age who is pregnant or breast-feeding or not willing to use an effective method of birth control during study treatment.\n\nKnown hypersensitivity to iron dextran Patients unwilling or unable to comply with the protocol or unable to give informed consent.\n\nKnown human anti-mouse antibodies",{"count":107,"type":20},[52],"Related donor Epstein-Barr Virus (EBV) specific cytotoxic T cells (CTLs) manufactured with the Miltenyi CliniMACS Prodigy Cytokine Capture System will be administered in children, adolescents and young adults with refractory EBV infection post Allogeneic Hematopoietic Stem Cell Transplantation (AlloHSCT), with primary immunodeficiencies (PID) or post solid organ transplant.\n\nFunding Source: FDA OOPD",[156,24],"Epstein-Barr Virus Infections",{"date":118,"type":29},{"date":159,"type":29},"2020-07-07",{"date":122,"type":20},{"name":64,"class":36},8]